CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Somewhat Bullish +45

CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management ...

📉 Amova Asset Management Americas Inc. trimmed its CRISPR Therapeutics stake by 5.3% in Q1, selling 104,236 shares and retaining a position worth $88.19 million.

📈 GSK plc acquired a new position in CRISPR Therapeutics in Q4 valued at approximately $168.89 million.

📈 Orbis Allan Gray Ltd raised its stake by 76.9% in Q2, now owning 2.76 million shares valued at $134.47 million.

📈 State Street Corp increased its holdings by 35.6% in Q2 to own 3.27 million shares worth $159.08 million.

📈 ARK Investment Management LLC grew its position by 7.5% in Q4, holding 10.52 million shares valued at $551.78 million.

🏦 Norges Bank purchased a new stake in CRISPR Therapeutics in Q4 valued at approximately $25.71 million.

👤 Insider Naimish Patel sold 3,786 shares for $210,577 to cover tax withholding obligations related to equity vesting.

💰 Company insiders collectively own 5.20% of CRISPR Therapeutics stock following the recent insider sale.

📊 The company reported a loss per share of $1.28 and revenue of $1.46 million for the quarter ending March 31st.

🧬 CRISPR Therapeutics focuses on developing gene-editing therapies using its CRISPR/Cas9 platform for serious diseases.

💉 Its lead program CTX001 is an ex vivo edited cell therapy designed to treat sickle cell disease and beta-thalassemia with Vertex Pharmaceuticals.

📈 The stock has a market capitalization of $4.53 billion and a price-to-earnings ratio of -7.55.

Bullish Signals
  • Major institutional investors including GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank have recently added to or initiated positions in CRISPR Therapeutics.
  • ARK Investment Management LLC significantly increased its stake by 7.5% in the fourth quarter, now holding over 10.5 million shares valued at $551.78 million.
  • State Street Corp lifted its holdings by 35.6% in the second quarter, increasing its position to 3.27 million shares worth $159.08 million.
  • Orbis Allan Gray Ltd raised its stake by 76.9% in the second quarter, acquiring an additional 1.2 million shares valued at $134.47 million.
  • GSK plc initiated a new position in CRISPR Therapeutics in the fourth quarter worth approximately $168.89 million.
Risk Factors
  • Insider Naimish Patel sold 3,786 shares for a total value of $210,577 to cover tax withholding obligations, reducing his personal holding by 16.36%.
Full Analysis
Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG by 5.3% during the first quarter, selling 104,236 shares and holding approximately 1.85 million shares valued at $88.19 million. The position represents about 1.2% of Amova's total holdings and ranks as its 26th largest position. Several other major institutional investors have adjusted their positions in the stock recently, with GSK plc initiating a new stake worth roughly $168.89 million in the fourth quarter. Orbis Allan Gray Ltd increased its CRISPR Therapeutics holding by 76.9% in the second quarter to own 2.76 million shares valued at $134.47 million, while State Street Corp lifted its position by 35.6% to hold 3.27 million shares worth $159.08 million. ARK Investment Management LLC grew its stake by 7.5% in the fourth quarter, now owning over 10.5 million shares valued at $551.78 million, and Norges Bank acquired a new position valued at approximately $25.71 million. Insider Naimish Patel sold 3,786 shares for a total value of $210,577 to cover tax withholding obligations related to the vesting of equity awards, reducing his personal holding by 16.36%. Following this transaction, he retains 19,357 shares valued at approximately $1.08 million. Company insiders collectively own 5.20% of CRISPR Therapeutics stock. The article also notes recent quarterly earnings results showing a loss per share of $1.28 and revenue of $1.46 million for the quarter. CRISPR Therapeutics is a biopharmaceutical company developing gene-editing therapies using its proprietary CRISPR/Cas9 platform to treat serious diseases through ex vivo and in vivo applications. Its lead program, CTX001, is an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent beta-thalassemia in collaboration with Vertex Pharmaceuticals. The company currently has a market capitalization of $4.53 billion and a negative price-to-earnings ratio of -7.55.